Skip to content
Recall Observatory FDA recall evidence

Drug product

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

D-0541-2026

April 24, 2026

Class II

Product summary

Firm
Lupin Pharmaceuticals Inc.
Event
Event 98809
Status
Ongoing
Classification
Class II
Quantity
217,621 pen injectors
Official record key
drug-enforcement:D-0541-2026

Official wording

Reason: Presence of particulate matter: a white thread-like structure in the cartridge

Code information: Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.

Distribution pattern: Nationwide within U.S

Derived failure modes

  • Foreign material or chemical contamination

    reason.foreign_material_chemical_contamination · v1.0.0

    particulate matter